Request Demo

Last update 20 Mar 2025

Norfloxacin

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, NFLX

+ [28]

Target

Bacterial DNA gyrase

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [2]

Active Indication

Dysentery, BacillaryGastrointestinal infectionTurista+ [12]

Inactive Indication

Cystitis

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.Central Pharmaceutical JSC No. 3

Arrotex Pharmaceuticals Pty Ltd.Startup

+ [1]

Inactive Organization

Merck Research Laboratories Massachusetts LLC

Eurofarma Laboratórios SA

Drug Highest PhaseApproved

First Approval Date

Japan (15 Feb 1984),

Infectious Diseases

Regulation-

Structure/Sequence

Molecular FormulaC16H18FN3O3

InChIKeyOGJPXUAPXNRGGI-UHFFFAOYSA-N

CAS Registry70458-96-7

Clinical Trials associated with Norfloxacin

CTR20241157

/ CompletedNot Applicable

诺氟沙星胶囊（0.1g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of norfloxacin capsules (0.1 g) in Chinese healthy volunteers under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择杏林制药株式会社为持证商的诺氟沙星片（商品名：BACCIDAL®，规格：100mg/片）为参比制剂，对哈药集团制药六厂生产、哈药集团制药总厂提供的受试制剂诺氟沙星胶囊（规格：0.1g/粒）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂诺氟沙星胶囊（规格：0.1g/粒）和参比制剂诺氟沙星片（商品名：BACCIDAL®，规格：100mg/片）的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, the norfloxacin tablets (trade name: BACCIDAL®, specification: 100mg/tablet) of which Xinglin Pharmaceutical Co., Ltd. is the licensee was selected as the reference preparation, and the test preparation norfloxacin capsules (specification: 0.1g/tablet) produced by Harbin Pharmaceutical Group Pharmaceutical Factory No. 6 and provided by Harbin Pharmaceutical Group Pharmaceutical Factory were tested for human bioequivalence under fasting administration. The absorption rate and degree of the drug in the test preparation were compared with those of the reference preparation to see if they were within an acceptable range, and the bioequivalence of the two preparations under fasting administration conditions was evaluated. Secondary research purpose: To observe the safety of oral administration of the test preparation norfloxacin capsules (specification: 0.1g/tablet) and the reference preparation norfloxacin tablets (trade name: BACCIDAL®, specification: 100mg/tablet) by healthy volunteers.

Start Date15 Apr 2024

Sponsor / Collaborator

Harbin Pharmaceutical Group Co. Ltd. General Pharm Factory

CTR20240282

/ CompletedNot Applicable

诺氟沙星胶囊在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹生物等效性试验研究方案

[Translation] Study plan for a single-center, randomized, open-label, two-formulation, single-dose, two-period, double-crossover fasting bioequivalence trial of norfloxacin capsules in healthy subjects

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下口服受试制剂诺氟沙星胶囊（规格：0.1g，持证商：广东恒健制药有限公司）与参比制剂诺氟沙星片（规格：0.1g，持证商：杏林制药株式会社，商品名：BACCIDAL®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂诺氟沙星胶囊和参比制剂诺氟沙星片在健康受试者中的安全性。

[Translation]

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsule (specification: 0.1g, license holder: Guangdong Hengjian Pharmaceutical Co., Ltd.) and the reference preparation norfloxacin tablet (specification: 0.1g, license holder: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsule and the reference preparation norfloxacin tablet in healthy subjects.

Start Date03 Mar 2024

Sponsor / Collaborator

Jiangmen Hengjian Pharmaceutical Co. Ltd.

CTR20230089

/ CompletedNot Applicable

诺氟沙星胶囊在健康受试者中空腹状态下的单中心、随机、开放、两制剂、单剂量、双周期、两序列、双交叉生物等效性试验研究方案

[Translation] A single-center, randomized, open-label, two-formulation, single-dose, two-period, two-sequence, double-crossover bioequivalence study protocol for norfloxacin capsules in healthy subjects under fasting condition

主要目的：以药代动力学参数作为主要终点评价指标，比较在空腹状态下口服受试制剂诺氟沙星胶囊（生产厂家：武汉同济现代医药科技股份有限公司）与参比制剂诺氟沙星片（持证商：杏林制药株式会社，商品名：BACCIDAL®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂诺氟沙星胶囊和参比制剂诺氟沙星片在健康受试者中的安全性。

[Translation]

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsules (manufacturer: Wuhan Tongji Modern Pharmaceutical Technology Co., Ltd.) and the reference preparation norfloxacin tablets (licensed manufacturer: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsules and the reference preparation norfloxacin tablets in healthy subjects.

Start Date22 Feb 2023

Sponsor / Collaborator

Wuhan Tongji Modern Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Norfloxacin

100 Translational Medicine associated with Norfloxacin

100 Patents (Medical) associated with Norfloxacin

19,478

Literatures (Medical) associated with Norfloxacin

01 Jul 2025·Separation and Purification Technology

Sophorolipid-modified nanoscale zero-valent iron activated peroxydisulfate for norfloxacin removal: Performance and reduction of agglomeration

Author: Fang, Zhanqiang ; Xue, Chengjie

Various modification methods such as metal doping, surface coating, emulsification and loading have been developed to deal with the challenge of controlling the release of high activity from nano zero-valent iron (nZVI).However, these modification methods are accompanied by risks such as secondary contamination.In this study, the sophorolipid modified nano zero-valent iron (SL-nZVI) was modified using environmentally friendly biosurfactants (sophorolipid) and used to activate peroxydisulfate (PDS) for degradation of norfloxacin (NOR).Characterization of the material showed that SL-nZVI was successfully prepared and distributed as a chain with a protective layer encapsulating the nZVI.This indicated that sophorolipid modification not only changed the hydrophilicity of nZVI particles, but also affected its ability to activate PDS, and that sophorolipid facilitated the transfer of nZVI electrons.The SL-nZVI + PDS system increased 3.2-fold for the NOR removal rate compared to nZVI + PDS.Multiple reactive oxygen species (ROSs) were proposed to be involved in PDS activation by SL-nZVI, including sulfate radical (SO₄·^-), singlet oxygen (¹O₂), superoxide radicals (·O^-₂), and high-valent ferrous oxide species (Fe^IV = O), hydroxyl radical (·OH) (¹O₂: 42.1 % > SO^·-₄: 28.7 % > ·O^-₂: 26.1 %).The SL-nZVI + PDS system still removed over 93 % of NOR in the presence of anions (except CO^2-₃) and natural organic matter, demonstrating excellent system resistance.In the SL-nZVI + PDS system, Fe²⁺ accelerated the activation of PDS, and almost all NOR was removed within 15 min at a low Fe²⁺ concentrations, Fe²⁺ accelerated the activation of PDS.This demonstrates that SL-nZVI is more favorable for the pollutant removal of practical wastewater.

01 Jul 2025·Separation and Purification Technology

Enhanced anti-fouling performance through integrated coagulation and membrane co-deposition modification for sustainable water treatment

Author: Liu, Ying ; Zhang, Xinbo ; Chang, Suyun ; Guo, Wenshan ; Wang, Huizhong ; Gong, Shichao ; Hao Ngo, Huu ; Zhang, Meng ; Wen, Haitao

Membrane fouling remains a significant challenge limiting the widespread use of membrane technol. in water treatment, particularly in ultrafiltration (UF) processes.To address this, we proposed a "coagulation + membrane modification" strategy to enhance fouling mitigation.The UF membranes were modified with polydopamine (PDA)-polyethyleneimine (PEI) and zwitterions via co-deposition.We investigated membrane morphol., physicochem. properties, hydrophilicity, permeability, and anti-fouling performance.Results showed that both PDA-PEI and zwitterions produced a more uniform and smoother deposited layer, while only PDA-PEI reduced the membrane contact angle by approx. 43 %, significantly improving surface hydrophilicity.Membranes modified with PDA-PEI exhibited exceptionally high permeability (159.02 L·m^-2·h^-1) and a high humic acid (HA) rejection rate (91.25 %).Addnl., the PDA-PEI-modified membrane demonstrated excellent antifouling properties, achieving a flux recovery ratio of over 95 % after three cycles.Furthermore, this strategy was applied to actual water treatment, where it outperformed single coagulation or membrane modification alone.The combined approach achieved removal rates of approx. 100 %, 87 %, 92 %, and 84 % for turbidity, TOC, HA, and NOR, resp., in real water samples.Notably, the strategy showed strong antifouling performance with a specific flux of 0.9 and a flux decline rate of just 10 %, highlighting its considerable potential for improving the fouling resistance of UF processes in water treatment.

01 Jul 2025·Separation and Purification Technology

Synergistic doped and loaded strategies to modify WO3 nanoflowers for efficient photocatalytic degradation of antibiotics through reactive oxygen species regulation

Author: Liu, Wen ; Li, Xiuze ; Yang, Xudong ; Qi, Juanjuan ; Guo, Liangyan

Developing an effective and powerful photocatalyst is important to its practical application in water treatment area, like emerging contaminants removal in water.Herein, through a synergistic strategy of N-doping and carbon quantum dots (CQDs)-loading on WO₃ nanoflowers, CQDs/N-WO₃ was designed, which exhibited excellent photocatalytic performance due to modulated electronic structure.Both exptl. characterization and theor. calculation confirmed that the synergistic effect accelerated the electron transfer ability from O2p to W5d, thus promoting the photogenerated electron and hole separation efficiency owing to the increased W5d orbital electron d.The optimum photocatalyst achieved 100 % removal of gatifloxacin (GAT) with a high reaction rate constant (k₁) of 0.055 min^-1 in 60 min under simulated solar light.Moreover, quenching experiment and radical detection demonstrated that the main reactive oxygen species (ROS) changed from ^•OH (WO₃ and N-WO₃) to O^•-₂ (CQDs/N-WO₃) for GAT removal.D. functional theory (DFT) calculation based on Fukui index further indicated the reactive sites of GAT were available for electrophilic attack.The internal mechanism was also deduced that after N doped and CQDs loaded on WO₃, narrowed band gap and increased utilization of visible light were observedMoreover, the high electron d. of N sites was more conducive to hole capture, and CQDs enhanced the electron transport as electron acceptor and transporter.The synergistic strategy of doping and loading opens a new perspective for modulating the electronic structure of catalysts, and provides a reference for regulating the ROS types in Fenton-like reactions for the removal of emerging contaminants in water.

News (Medical) associated with Norfloxacin

09 Feb 2021

·www.globenewswire.com

Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. Market for Penicillin and Combination Drugs Segment to Grow at Highest CAGR during 2020-2027. The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent. Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment. R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc. Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs. Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in boots pharmacies throughout the UK. Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults. In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period. Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market. Key Topics Covered: 1. Introduction 2. Urinary Tract Infection Treatment Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Urinary Tract Infection Treatment Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.3 Expert Opinion 5. Urinary Tract Infection Treatment Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Growing Urinary Tract Infections 5.1.2 Aging Population 5.1.3 Emerging Computing Technologies for Urine Diagnostics 5.2 Market Restraints 5.2.1 Associated Effects of Medication 5.3 Market Opportunities 5.3.1 R&D in UTI Treatment 5.4 Future Trends 5.4.1 Nutritional Supplement in UTI 6. Urinary Tract Infection Treatment Market - Global Analysis 6.1 Global Urinary Tract Infection Treatment Market Revenue Forecast and Analysis 6.2 Global Urinary Tract Infection Treatment Market, By Geography - Forecast and Analysis 6.3 Market Positioning of Key Players 7. Urinary Tract Infection Treatment Market Analysis - By Drug Class 7.1 Overview 7.2 Urinary Tract Infection Treatment Market Revenue Share, by Drug Class (2019 and 2027) 7.3 Penicillin and Combinations 7.3.1 Overview 7.3.2 Penicillin and Combinations: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.3.3 Amoxicillin 7.3.4 Amoxicillin and Clavulanate Potassium 7.4 Quinolones 7.4.1 Overview 7.4.2 Quinolones: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.4.3 Ciprofloxaxin 7.4.4 Levofloxaxin 7.4.5 Nalidixic Acid 7.4.6 Norfloxacin 7.4.7 Others 7.5 Cephalosporin 7.6 Aminoglycoside Antibiotics 7.7 Sulphonamides 7.8 Nutritional Supplements 7.8.1 Overview 7.8.2 Nutritional Supplements: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.8.3 Cranberry Supplements 7.8.4 D-Mannose 7.8.5 Probiotics 7.8.6 Vitamin-C 8. Urinary Tract Infection Treatment Market Analysis - By Indication 8.1 Overview 8.2 Urinary Tract Infection Treatment Market Revenue Share, by Indication (2019 and 2027) 8.3 Complicated Urinary Tract Infections 8.4 Uncomplicated Urinary Tract Infections 9. Urinary Tract Infection Treatment Market Analysis - By Distribution Channel 9.1 Overview 9.2 Urinary Tract Infection Treatment Market Revenue Share, by Distribution Channel (2019 and 2027) 9.3 Hospital Pharmacies 9.4 Retail Pharmacies & Drug Stores 9.5 Gynaecology and Urology Clinics 9.6 Online Drug Stores 10. Urinary Tract Infection Treatment Market - Geographic Analysis 11. Impact of COVID-19 Pandemic on Global Urinary Tract Infection Treatment Market 12. Urinary Tract Infection Treatment Market-Industry Landscape Companies Mentioned Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd Mylan N.V. ALLERGAN Pfizer Inc. Cipla Ltd F. Hoffmann-La Roche Ltd Shionogi Inc. Amway DuPont Nutrition & Biosciences For more information about this report visit CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Collaborate

100 Deals associated with Norfloxacin

External Link

KEGG	Wiki	ATC	Drug Bank
D00210	Norfloxacin	J01MA06 S01AE02	DB01059

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dysentery, Bacillary	Australia	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Gastrointestinal infection	Australia	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Turista	Australia	Arrotex Pharmaceuticals Pty Ltd.Startup	13 Nov 2001
Corneal Ulcer	Japan	KYORIN Pharmaceutical Co., Ltd.	24 Nov 1992
Blepharitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Blepharitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Conjunctivitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Keratitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Gonorrhea	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Prostatitis	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Salmonella Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Typhoid Fever	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Urinary Tract Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Infectious Diseases	Japan	KYORIN Pharmaceutical Co., Ltd.	15 Feb 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystitis	Preclinical	-	Eurofarma Laboratórios SA	01 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03584724 (CTgov)	Early Phase 1	Uveitis	49	Norflo Oro (Norflo Oro)	ttssbwslgv(kyodmotymv) = cgmceowgix srklywopwa (cfbhvrroqr, utangjmwne - xnshhqvxsm) View more	-	28 Mar 2022
				Placebo for Norflo Oro (Placebo for Norflo Oro)	ttssbwslgv(kyodmotymv) = vaiwtdqtgo srklywopwa (cfbhvrroqr, xuqluenxaf - ngoruzxqxo) View more
NCT03695705 (Pubmed \| J Clin Exp Hepatol)	Phase 3	Spontaneous bacterial peritonitis	132	Rifaximin	ljrvbvhxvy(vkjdizgcvp) = ufktarztey kouyotrjhv (xwuefbqfvo ) View more	-	01 Mar 2022
				Norfloxacin	ljrvbvhxvy(vkjdizgcvp) = qpxkczuawv kouyotrjhv (xwuefbqfvo ) View more
EASL2020	Not Applicable	Spontaneous bacterial peritonitis	1,626	Norfloxacin	gyeiztqigw(vkowvtqdrz) = wmofsmtnpo rsnlxnubne (vmdamvkrcq ) View more	Negative	27 Aug 2020
				Placebo	-
NCT04159870 (Pubmed \| Curr Drug Targets)	Phase 3	Spontaneous bacterial peritonitis	973	Rifaximin plus norfloxacin	ocwocbfsaq(stuurayibd): RR = 0.58 (95% CI, 0.37 - 0.92), P-Value = 0.02 View more	Positive	01 Jan 2019
				Norfloxacin-based regimen
NCT01037959 (Pubmed \| Gastroenterology)	Phase 3	Fibrosis	291	Norfloxacin 400 mg	qjqievgptp(zuiyiqjbmg) = agqksxniqa ycwrrutiyw (iwtnoocfvq )	-	01 Dec 2018
				Placebo	qjqievgptp(zuiyiqjbmg) = aioyqefauq ycwrrutiyw (iwtnoocfvq )
PA031 (AAO2003)	Not Applicable	-	206	Levofloxacin	woihrkpjfp(gigncxoamj) = zchuyoaucw nvagarmlts (cvnqhilegz )	Positive	17 Nov 2003
				Norfloxacin	woihrkpjfp(gigncxoamj) = uajhismbtu nvagarmlts (cvnqhilegz )
ARVO2002	Not Applicable	-	-	Levofloxacin 0.5%	(yibtxlikkl) = mjcvoxtyik xnoiivcyhi (qmkvfzcyrp, 3.53)	-	01 Dec 2002
				Norfloxacin 0.3%	(yibtxlikkl) = yrcdifswtt xnoiivcyhi (qmkvfzcyrp, 1.18)
NCT04159870 (Pubmed \| Gastroenterology)	Phase 3	Gastrointestinal Hemorrhage	119	Norfloxacin	stdckswexr(bupzwsuwan) = iiknvlajlu lqlsuiaeuh (dydguncnbb ) View more	-	01 Oct 1992
				Norfloxacin (Control)	opsimcujnm(ywlqyrakit) = foloytcmly qnbqhvbbcs (yzwudbcwdj ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis